# A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

> **NCT00627627** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **MedImmune LLC** · enrollment: 56 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** IPI-504

## Key facts

- **NCT ID:** NCT00627627
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-04
- **Primary completion:** 2010-02
- **Final completion:** —
- **Target enrollment:** 56 (ESTIMATED)
- **Why stopped:** Redirect focus of the indication
- **Last updated:** 2010-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00627627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00627627, "A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00627627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*